Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US4781601046
Ticker JNJ
Company JOHNSON & JOHNSON
Currency $
Price
Aware Investor Index (AII) 4.7110
Recommendation BUY
P/E 27.62
ROE 17.70 %
Capitalization 347,758,827,000 $
Dividend Yield 2.39 %
P/S 4.96
AII Position 141
P/E Position 349
ROE Position 196
Capitalization Position 9
Dividend Yield Position 268
Sales 70,074,000,000 $
10-Year Average Earnings 12,592,700,000 $
Shares Outstanding 2,812,900,000
Equity 71,150,000,000 $
Dividend per Share 2.95 $
Industry Personal Care
Country United States
JOHNSON & JOHNSON Investor Relations Web Site http://www.investor.jnj.com/investor-relations.cfm







Sales:

YEAR MONTH AMOUNT
2015 12 70,074,000,000.00 $
2014 12 74,331,000,000.00 $
2013 12 71,312,000,000.00 $

Earnings:

YEAR MONTH AMOUNT
2015 12 15,409,000,000.00 $
2014 12 16,323,000,000.00 $
2013 12 13,831,000,000.00 $
2012 12 10,514,000,000.00 $
2011 12 9,672,000,000.00 $
2010 12 13,334,000,000.00 $
2009 12 12,266,000,000.00 $
2008 12 12,949,000,000.00 $
2007 12 10,576,000,000.00 $
2006 12 11,053,000,000.00 $

Equity:

YEAR MONTH AMOUNT
2015 12 71,150,000,000.00 $
2014 12 69,752,000,000.00 $
2013 12 74,053,000,000.00 $
2012 12 64,826,000,000.00 $
2011 12 57,080,000,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2015 12 2,812,900,000
2014 12 2,863,900,000
2013 12 2,877,000,000
2012 12 2,812,600,000
2011 12 2,775,300,000

 












Bloomberg News for JOHNSON & JOHNSON:



Google News for JOHNSON & JOHNSON:

Seeking Alpha - 12 hours ago
Johnson & Johnson Raises Guidance, Now What?
On Tuesday, medical conglomerate Johnson & Johnson (JNJ) posted quarterly earnings in which management upped full-year 2018 guidance ...
MarketWatch
Johnson & Johnson Q2 Earnings Beat Led By A Solid Growth In ...
Johnson & Johnson (NYSE:JNJ) recently posted a better than expected Q2 performance with an 11% jump in sales, led by a ramp up in ...
CNBC
Strength to Boost your Portfolio: Johnson & Johnson (JNJ) and The ...
Stoffels Paulus, Exec VP, Chief Scientific Off, sold 155,342 shares of the Johnson & Johnson (NYSE:JNJ) in an exchange that happened on ...
U.S. News & World Report
Johnson & Johnson (JNJ) Closes 1.01% Down on the Day for July 18
Shares of Johnson & Johnson (JNJ) ended the trading day Wednesday at $127.80, representing a move of -1.01%, or $1.31 per share, ...
Forbes - 8 hours ago
J&J lead attorney: We won't be 'intimidated' into removing talc ...
Johnson & Johnson lead attorney Bart Williams told CNBC on Friday that talc-based products, such as Baby Powder and other cosmetics, have ...
Seeking Alpha
Johnson & Johnson: Trouble Ahead
My previous research has long claimed that Johnson & Johnson (JNJ) would struggle as the stock price wasn't justified by the growth rate.
Motley Fool
Johnson & Johnson CEO defends drug prices, calls for changes in ...
Johnson & Johnson CEO Alex Gorsky called for changes in the way ... with analysts Tuesday after the release of J&J's second-quarter results.
MarketWatch
J&J Unit to Sell Sylvant Rights to UK Drugmaker Eusa Pharma
A unit of U.S. health-care giant Johnson & Johnson has agreed to sell global rights to a treatment for a rare blood disorder to Britain's Eusa ...
NMSU Nеws - 8 hours ago
Johnson & Johnson (JNJ) Reaches $128.95 After 4.00% Up Move ...
The stock of Johnson & Johnson (NYSE:JNJ) is a huge mover today! The stock increased 3.42% or $4.2601 during the last trading session, ...
Equities.com - 6 hours ago
Healthcare ETFs in Focus Following JNJ Q2 Results
The Q2 earnings season has commenced and Johnson & Johnson JNJ was the first drug company to report on Jul 17, before the opening bell.


Back